Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
| ▸ | METAP1 | P53582 | 4/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 6/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269444 | 0.87 | ACHE (0.67) | CYP19A1SIGMAR1METAP1HDAC1MAOB | |
| SCHEMBL3314894 | 0.87 | CYP19A1 (1.00) | CYP19A1SIGMAR1METAP1HDAC1 | |
| Bromide SCHEMBL2334441 | 0.86 | ACHE (0.68) | CYP19A1SIGMAR1METAP1HDAC1MAOB | |
| Hydrochloric Acid SCHEMBL2332692 | 0.86 | ACHE (0.66) | CYP19A1SIGMAR1METAP1HDAC1MAOB | |
| SCHEMBL30275056 | 0.84 | CYP19A1 (0.80) | CYP19A1SIGMAR1MAOBACHEHTR1A | |
| SCHEMBL3761876 | 0.84 | CYP19A1 (0.80) | CYP19A1SIGMAR1MAOBACHEHTR1A | |
| SCHEMBL28733987 | 0.84 | CYP19A1 (0.80) | CYP19A1SIGMAR1MAOBACHEHTR1A | |
| SCHEMBL8064902 | 0.83 | CYP19A1 (0.59) | CYP19A1SIGMAR1METAP1HDAC1ACHE | |
| SCHEMBL19748689 | 0.83 | CYP19A1 (0.63) | CYP19A1SIGMAR1METAP1HDAC1ACHE | |
| SCHEMBL10033952 | 0.81 | SIGMAR1 (0.70) | CYP19A1SIGMAR1MAOBACHEHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854701-A | Benzofuranoxapine compound and synthesis method thereof | 江苏师范大学 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023122754-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING GB13, GB22 AND HIMGALINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-112961086-B | 2-methylene-1-indanone derivative and synthesis method thereof | 齐鲁工业大学 | 2022-10-21 | — | — | CN | disclosed |
| CN-111499503-B | Method for synthesizing alpha-alkylated ketone in water | 南京理工大学 | 2022-04-08 | — | — | CN | disclosed |
| CN-112961086-A | 2-methylene-1-indanone derivative and synthesis method thereof | 齐鲁工业大学 | 2021-06-15 | — | — | CN | disclosed |
| CN-111499503-A | Method for synthesizing α -alkylated ketone in water | 南京理工大学 | 2020-08-07 | — | — | CN | disclosed |
| CN-106478325-B | A method of synthesis alpha-alkyl ketone | 南京理工大学 | 2019-06-25 | — | — | CN | disclosed |
| CN-105439787-B | Method for synthesizing α -alkyl ketone | 南京理工大学 | 2018-02-13 | — | — | CN | disclosed |
| WO-2017223160-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2017-12-28 | — | — | WO | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| EP-1613315-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| CN-1709860-A | Benzal indone and benzyl indone derivative(s), and its preparing method and use | UNIV ZHEJIANG (CN) | 2005-12-21 | — | — | CN | disclosed |
| EP-1261588-B1 | IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS | ORION CORP (FI) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004087142-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
| WO-2001051472-A9 | NEW IMIDAZOLE DERIVATIVES | ORION CORP (FI) | 2003-01-23 | — | — | WO | disclosed |
| EP-1261588-A1 | NEW IMIDAZOLE DERIVATIVES | ORION CORPORATION (FI) | 2002-12-04 | — | — | EP | disclosed |
| US-6388090-B2 | IMIDAZOLE DERIVATIVES CONTAINING BICYCLIC AROMATIC OR AN HETEROCYCLIC RING FUSED WITH BENZENE EXHIBIT AFFINITY FOR ALPHA2 ADRENOCEPTORS SO TREATS THE DISEASE AFFECTED BY ALPHA2 ADRENOCEPTORS, E.G. NUROLOGICAL, PSYCHIATRIC OR COGNITION | ORION CORPORATION (FI) | 2002-05-14 | — | — | US | disclosed |
| US-20010056109-A1 | Imidazole derivatives | ORION CORPORATION (FI) | 2001-12-27 | — | — | US | disclosed |
| WO-2001051472-A1 | NEW IMIDAZOLE DERIVATIVES | ORION CORPORATION (FI) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056109-A1 | Imidazole derivatives | ADRB2, ADRB1, ADRA1D | CYP19A1 1178/4885SIGMAR1 82/4885METAP1 2475/4885 |
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | CYP19A1 2314/4885SIGMAR1 2522/4885METAP1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.